upadacitinib

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

RINVOQ — ABBVIE, approved 2026-06-30 (NDA218347).

Most reported adverse events (US / FAERS)

41,105 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

pain

5,132

arthralgia

4,538

drug ineffective

4,403

covid-19

3,175

rheumatoid arthritis

Medicines containing this active substance

1 medicines

Rinvoq

Authorised

🇺🇸 Also approved in the US (FDA)

RINVOQ — ABBVIE, approved 2026-06-30 (NDA218347).

Most reported adverse events (US / FAERS)

41,105 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

pain

5,132

arthralgia

4,538

drug ineffective

4,403

covid-19

3,175

rheumatoid arthritis

3,152

pain in extremity

2,692

fatigue

2,552

surgery

2,396

fall

2,385

headache

1,873

pneumonia

1,858

therapy interrupted

1,800

death

1,784

diarrhoea

1,692

back pain

1,673